Search results
Found 10174 matches for
-
Long Noncoding RNAs CUPID1 and CUPID2 Mediate Breast Cancer Risk at 11q13 by Modulating the Response to DNA Damage.
2 April 2018
Breast cancer risk is strongly associated with an intergenic region on 11q13. We have previously shown that the strongest risk-associated SNPs fall within a distal enhancer that regulates CCND1. Here, we report that, in addition to regulating CCND1, this enhancer regulates two estrogen-regulated long noncoding RNAs, CUPID1 and CUPID2. We provide evidence that the risk-associated SNPs are associated with reduced chromatin looping between the enhancer and the CUPID1 and CUPID2 bidirectional promoter. We further show that CUPID1 and CUPID2 are predominantly expressed in hormone-receptor-positive breast tumors and play a role in modulating pathway choice for the repair of double-strand breaks. These data reveal a mechanism for the involvement of this region in breast cancer.
-
Elevated homocysteine andN-methyl-d-aspartate-receptor antibodies as a cause of behavioural and cognitive decline in 22q11.2 deletion syndrome.
23 March 2018
A 19-year-old male with 22q11.2 deletion syndrome presented with a 4-year history of cognitive decline and symptoms suggestive of atypical psychosis. Potential for elevated homocysteine and NMDA-receptor antibodies in the pathogenesis of his symptoms was investigated. He had elevated blood homocysteine level (18.7 μmol/l), low-normal vitamin B12 and folate levels and was positive for NMDA-receptor antibodies. Treatment with daily folinic acid (0.8 mg) and vitamin B12 (1 mg) led to dramatic improvement in his cognitive and behavioural presentation. Subsequent plasma exchange resulted in a further, significant clinical improvement. Homocysteine levels and NMDA-R antibodies should be investigated as potential causes of behavioural and cognitive symptoms in patients with 22q11.2 deletion syndrome.
-
Intergenic disease-associated regions are abundant in novel transcripts.
23 March 2018
Genotyping of large populations through genome-wide association studies (GWAS) has successfully identified many genomic variants associated with traits or disease risk. Unexpectedly, a large proportion of GWAS single nucleotide polymorphisms (SNPs) and associated haplotype blocks are in intronic and intergenic regions, hindering their functional evaluation. While some of these risk-susceptibility regions encompass cis-regulatory sites, their transcriptional potential has never been systematically explored.To detect rare tissue-specific expression, we employed the transcript-enrichment method CaptureSeq on 21 human tissues to identify 1775 multi-exonic transcripts from 561 intronic and intergenic haploblocks associated with 392 traits and diseases, covering 73.9 Mb (2.2%) of the human genome. We show that a large proportion (85%) of disease-associated haploblocks express novel multi-exonic non-coding transcripts that are tissue-specific and enriched for GWAS SNPs as well as epigenetic markers of active transcription and enhancer activity. Similarly, we captured transcriptomes from 13 melanomas, targeting nine melanoma-associated haploblocks, and characterized 31 novel melanoma-specific transcripts that include fusion proteins, novel exons and non-coding RNAs, one-third of which showed allelically imbalanced expression.This resource of previously unreported transcripts in disease-associated regions ( http://gwas-captureseq.dingerlab.org ) should provide an important starting point for the translational community in search of novel biomarkers, disease mechanisms, and drug targets.
-
Simon Lovestone knighted in Queen’s Birthday honours
19 June 2017
Professor Simon Lovestone, MRCPsych, Professor of Translational Neuroscience, is knighted for services to neuroscience research.
-
BBC's World at One investigates world's biggest study into Alzheimer's Disease
5 July 2017
Professors Clare Mackay and Simon Lovestone, reveal details of the ‘Deep and Frequent Phenotyping Study’, led here at the Department of Psychiatry.
-
OMC awarded major Wellcome public engagement grant
9 August 2017
The Oxford Mindfulness Centre, based in the Department of Psychiatry, has been awarded a major Public Engagement grant from Wellcome.
-
'Highly hazardous pesticides: policies should focus on bans, rather than secure storage', studies suggest
16 August 2017
Global policies on access to highly hazardous pesticides – commonly ingested in acts of self-poisoning and suicide in rural Asia – should focus on national bans, rather than safe storage, according to two studies in The Lancet and The Lancet Global Health journals.
-
Study shows adolescent depression increases risk for violence
9 August 2017
The findings of research conducted by Dr Rongqin Yu under the supervision of Profs Seena Fazel and Guy Goodwin with collaborators in Finland and the Netherlands emphasize the need for early detection and intervention.
-
Treating depression in cancer hugely increases quality of life, but probably not length of life
14 March 2018
Professor Michael Sharpe and colleagues identify that treating depression doesn’t make cancer patients live longer, but it does make lives immeasurably better.
-
'Tapping the full potential of Europe's health data'
17 April 2018
A focus on the EU and industry-funded EMIF project, co-coordinated by Professor Simon Lovestone, which has created a secure online platform consolidating metadata from a wide variety of sources.
-
2018 Away Day in Pictures
10 January 2018
On 9 January 2018 the Department of Psychiatry came together in the Richard Doll Building, Old Road Campus, to share ideas and latest research.
-
Prof Simon Lovestone cycles to Buckingham Palace to receive knighthood
6 December 2017
Professor Lovestone, who is receiving a knighthood on 7 December, in recognition of his research into Alzheimer's disease, will be cycling to the Palace as part of a 300 mile ride for Alzheimer's Research UK.
-
The hospital costs of self-harm
8 September 2017
Study reveals the health service costs for hospital care of people who self-harm, emphasising the need for effective clinical services and prevention initiatives.
-
DPhil and MSc by Research
17 April 2018
The DPhil at Oxford has few taught courses, and starts from the outset with expecting a high degree of independence from its graduate students
-
Links
1 November 2012
-
World Association for Social Psychiatry (WASP)
1 November 2012
-
Training for Graduate Students
1 November 2012
-
Acknowledgements
1 November 2012
-
Paranoia: The 21st Century Fear
1 November 2012
-
Know Your Mind
1 November 2012
-
Old Age Psychiatry CPD Meeting
20 April 2016
-
Old Age Psychiatry CPD Meeting
12 October 2016
-
Earliest relationships and community life: impact and outcomes
18 October 2016
-
Autism in Africa: current state
8 November 2016
-
Self-harm in young people: an update
7 March 2017
-
Work with us
18 October 2016
-
News
17 April 2018
-
Events
13 May 2016
-
Announcements
18 October 2016
-
Research projects
21 October 2014
• APOE • OPDC • Whitehall • CHA • UKDP • conBRIO • other (PTSD, COMT, etc)
-
Announcements
26 September 2014
-
Projects
9 April 2018
-
Downloads
30 June 2017
-
Clinical Trials
9 April 2018
-
Volunteers needed for a study investigating the effects of mental exercises
22 January 2018
You would be invited to the Department of Psychiatry (Warneford Hospital) for two study sessions. Both sessions would take approximately 60 to 90 minutes. Between the sessions you would be assigned a brief mental exercise (taking approximately 10 minutes per day) that you carry out for 7 days. After this training period, your performance on a range of computerized psychological tasks will be assessed.
-
Dynamics of perceptual decision making
17 April 2018
During this study you will learn and perform a task that involves judging the direction of motion of clouds of moving dots. You will participate in a maximum of 4 sessions; first you will learn how to do the task on a computer. Then you will do 1-2 sessions performing the task while we record your brain activity using magnetoencephalography (MEG). MEG is a safe neuro-imaging technique that records the weak magnetic fields produced by the synchronised firing of neurons in the brain. MEG sessions will last up to 2 hours. Finally, we will make a 3D image of your brain using magnetic resonance imaging (MRI) which we will use to localise the neural generators of the MEG signals.
-
VOLUNTEERS NEEDED FOR ONE-TO-ONE INTERVIEW ON BRAIN HEALTH
14 March 2018
We are conducting a research study to investigate people’s perceptions of the brain and brain health (Ethics Approval Reference: R56033/RE001). The study is led by the EU-funded Lifebrain consortium (www.lifebrain.uio.no).
-
Can non-drug antidepressant treatments influence the way the human brain processes information?
28 September 2017
Ethics Approval Reference: R48997/RE003
-
Volunteers Needed for Learning Study
13 December 2017
We are looking for healthy volunteers aged between 18 to 65 to improve our understanding of how people learn which are the best choices to make in day-to-day living. The study will take about 2 hours of your time and will take place in the Department of Psychiatry at the Warneford Hospital. During the study you would be asked to complete some simple tasks while an eye tracker device measures the changes in your pupil size.
-
How does your problem solving ability relate to measures of heart rate and hormonal function?
6 November 2017
Healthy male volunteers aged 18-40 years are needed for a study investigating the relationship between abilities on computerized problem solving tasks and measures of heart rate, skin sweating, and hormonal function. Central University Research Ethics Committee number: R53870/RE001
-
The effect of losartan on fear learning
6 September 2017
We are looking for healthy volunteers aged 18-40 years and fluent in English to take part in a study investigating how a single dose of the medication losartan affects learning and information processing, using a simple computer task. Losartan is currently used to treat high blood pressure. However, we think that it may also enhance the effectiveness of psychological therapies such as Cognitive-Behaviour Therapy. The study involves three appointments of about 5 hours in total.
-
Volunteers needed for Dementia Prevention Study: European Prevention of Alzheimer’s Dementia (EPAD)
11 April 2018
The European Prevention of Alzheimer’s Dementia (EPAD study) aims to address the urgent need for new treatments designed to prevent Alzheimer’s Dementia. The main study objectives are to: 1. Learn and understand better the factors involved in developing Alzheimer’s dementia. 2. To develop new treatments more quickly which are hoped to prevent Alzheimer’s dementia.
-
Ebselen as an add-on treatment in hypo/mania
31 October 2017
Lithium can stabilise the highs and lows of mood but requires careful monitoring. We are interested in a new lithium-like medicine called ebselen which might help improve recovery from acute hypo/manic episodes. The study involves adding ebselen to your usual medication during an acute episode of hypo/mania.
-
OxCaMS
5 September 2017
Have you been experiencing mood swings? Have you recently engaged in risky behaviour, been so hyper that you got into trouble, had much more energy than usual and/or been so irritable that you started fights?
-
Oxford Autism
15 April 2013
The Oxford Autism Research Centre brings together scientists, charities and service providers from across Oxfordshire and the surrounding regions.
-
Child & Adolescent Psychiatry
1 November 2012
We aim to promote the healthy mental and physical development of children and their families in adversity. Our work focuses on elucidating the mechanisms underlying disturbed development and in creating appropriate interventions.
-
Collaborative Oxford Network for Bipolar Research to Improve Outcomes
2 July 2014
Our aims and objectives will be delivered through four interlinked research themes: the first three target key phenotypic and pathophysiological aspects of mood instability and bipolar disorder; together they feed into the fourth, therapeutically-focused, theme:
-
Neural Correlates of Gene Function
2 October 2015
Behaviour Brain Brain imaging Cognitive Cognitive models Decision-making Dopamine Functional imaging Genetics Magnetic Resonance Imaging (MRI) Magnetoencephalography (MEG) Mood Neuroimaging Neuroscience Pharmacology Risk factors Schizophrenia Stress
Our research aims to understand how individual genes contribute to the complex brain functions that are impaired in people with psychiatric disorders. By understanding these links we hope to improve treatments for these disorders.
-
Psychological Medicine Research
1 November 2012
The Oxford Psychological Medicine Research group aims to improve the lives of people with medical-psychiatric multimorbidity through high quality research. We research the psychological and psychiatric problems of patients with medical conditions, develop innovative treatments to address these, and test the treatments in rigorous randomised trials.
-
Translational Neurobiology of Psychosis
1 November 2012
We are interested in the molecular and neural basis of schizophrenia and bipolar disorder, and how the risk genes for these disorders operate. We use a range of platforms, methods, and collaborations, to carry out this work.
-
Oxford Cognitive Approaches to Psychosis
1 November 2012
We investigate why people experience hallucinations and delusions, and use that knowledge to develop truly effective treatments for these problems. Our targeted interventions for paranoia are now being tested in randomized controlled clinical trials.
-
Psychopharmacology and Emotion Research Laboratory
1 November 2012
Anxiety Behaviour Behavioural models Bipolar Brain Brain function Brain imaging Cognitive Cognitive models Depression Experimental Functional imaging Mental illness Neuroimaging Neuroscience Psychology Treatment
We explore how the brain processes emotional information and how this is influenced by brain chemicals and medicines. This helps us to understand disorders such as depression and anxiety and to understand and contribute to the development of drug and psychological treatments.
-
Neurobiology and Experimental Therapeutics
26 October 2012
We are dedicated to testing and developing new ways of improving treatments for psychiatric disorders, and maintaining brain health during aging. A significant proportion of people suffering from disturbances of mood and memory, do not respond to the available medication, and so there is an urgency to supplement or provide an alternative to current therapies.
-
Emotion & Motivation
1 November 2012
Bipolar Dependence Depression Mood Schizophrenia Substance abuse
-
Human Development
1 November 2012
Anxiety Brain Depression HIV Neuroimaging PTSD Parenting Refugees and asylum seekers Treatment trials
The research is predominantly concerned with the development of young children in the face of adversity. There are two objectives. The first has been to elucidate the environmental mechanisms underlying children’s development in adversity. The second has been to use this understanding to develop interventions to enhance children’s development and support their families.
-
Whitehall II Study 30th Anniversary Celebration Event
2015 marked the 30th anniversary of the Whitehall II Study. To celebrate the achievements of the past 30 years, a one-day celebration event was held at UCL on Wednesday 25th November 2015. Over 150 people attended including Whitehall researchers, collaborators and a representative group of participants from the Whitehall II cohort. The link leads to the day's talks and presentations
-
Whitehall II Study 30th Anniversary Celebration Event
2015 marks the 30th anniversary of the Whitehall II Study. To celebrate the achievements of the past 30 years, a one-day celebration event was held at UCL on Wednesday 25th November 2015. Over 150 people attended including Whitehall researchers, collaborators and a representative group of participants from the Whitehall II cohort.
-
Event types
4 November 2017